Home > Resources > Whitepapers > Opposites attract Blurring the lines between small and large molecule manufacturing

Opposites attract Blurring the lines between small and large molecule manufacturing

June 28, 2018

The biopharmaceutical industry has grown impressively in recent years, with its global compound growth rate (CAGR) estimated to reach 8.5% between 2018-2023, outstripping traditional New Chemical Entity sectors1 . Emerging novel drugs show huge therapeutic potential, such as antibodydrug conjugates (ADCs), checkpoint inhibitors and viral gene therapy. But as the industry grows, it may face potential issues securing an expanded supply chain.

Spotlight

BTI Biotechnology Institute

BTI Biotechnology Institute is a Spanish multinational company specialising in biomedicine and biotechnology whose activity focuses on two areas: regenerative medicine and oral implantology. It was founded in 1999 by Dr. Eduardo Anitua, the company’s president and scientific director. Oral Implantology: BTI’s implant system is one of the most versatile on the market, an implant system that adapts to the patient, not the other way around, as it offers an extremely wide range of solutions tailored to each need, so that dental professionals can approach their treatments with the utmost confidence and predictability.

OTHER WHITEPAPERS

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

DIGITAL BIOTECH IS MISSION-CRITICAL TO MODERNA

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.

Cell and Gene Therapy Clinical Trials

whitePaper | November 8, 2022

Using experienced-based best practices and documented tools, ICON has conducted over 63 CGT trials across multiple therapeutic areas from haematology-oncology torare and orphan diseases.

A Playbook for Emerging Biotechs

whitePaper | March 24, 2023

The global biotech industry continues to witness growth with an estimated market size of nearly $300B, despite the current state of the funding environment

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.